PGXperts: Pioneers in the field of pharmacogenetics

22.05.2025

At a time when personalized medicine is becoming increasingly important, PGXperts has positioned itself as a pioneer in pharmacogenetics. The young company from Fürth focuses on using genetic analyses to optimize drug therapies and thus offer patients tailor-made treatment options. At the heart of this is the vision of making medical therapies safer and more effective while reducing healthcare costs.

The PGXperts team consists of 38 experts from various disciplines who are working together to harness genetic information. With innovative technologies and a comprehensive understanding of molecular processes, the company supports doctors and clinics in making well-founded treatment decisions. The focus here is not only on patient care, but also on improving the safety of drug therapy in hospitals and doctors' surgeries.

A key element of their work is the analysis of pharmacogenetic data. This makes it possible to identify individual genetic markers that can influence the effect of drugs. By precisely evaluating this data, PGXperts can identify potential risks, such as side effects or drug interactions, at an early stage. The attending physician can take this information into account when making treatment decisions. A classic example of this is certain chemotherapeutic agents, the dosage of which can be adjusted depending on the patient's genetic predisposition.

In addition to pharmacogenetic analysis, PGXperts also relies on digital tools such as PGXperts PRiM, a system that is integrated into hospitals to monitor drug therapy safety during the entire hospital stay. In addition to genetic influencing factors, clinical and demographic risks, such as interactions between medications and lifestyle habits, are clearly presented to users according to severity.

The PGXperts success story began around ten years ago, when a personal event led the current CEO to recognize the potential of pharmacogenetics in medical care. Since then, PGXperts has developed from being part of a consulting company into an independent start-up and is now represented in over 30 hospitals in Germany.

PGXperts' vision for the future is clear: they want to help make pharmacogenetics an integral part of medical care - with the aim of sustainably improving the safety and efficacy of therapies. At a time when personalized medicine is becoming increasingly important, PGXperts could play a key role - not only in Germany, but also internationally.

The company is an impressive example of how innovative technologies can be used to improve patient care. The collaboration with Bayern Innovativ makes it possible to create targeted synergies between research, start-ups and established players in the healthcare sector. Within the network, PGXperts provides important impetus for the future of personalized medicine.

Further information about PGXperts can be found here.